Veracyte, Inc. (VCYT)

NasdaqGM • Currently down 2.14 (-4.79%) in today's trading session

2 members of Congress have disclosed 12 trades in Veracyte, Inc. (VCYT) via STOCK Act filings. The most recent disclosure was a purchase by Gilbert Cisneros on 3 March 2026. The most active traders have been Gilbert Cisneros (10) and Josh Gottheimer (2). Aggregate disclosed activity totals roughly $64K in purchases and $32K in sales (midpoint estimates from bracketed disclosure amounts).

Veracyte, Inc. is currently trading at $42.53, positioned at 42% of its 52-week range ($29.45 – $60.91).

Want to automatically copy Pelosi trades?

Mirror Nancy Pelosi's portfolio with just one click on eToro.

Claim Free AssetCopy Automatically with eToro

Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.

Past Performance is not an indication of future results.

Current Price
$42.53
24h Change
-2.14 (-4.79%)
52 Week Range
$29.45–$60.91
View on NASDAQ

Veracyte, Inc. Price History and Technical Analysis

Interactive Chart

Congressional Trading Activity for VCYT

Select to highlight on chart
5 transactions
Compliance: 92%
Gilbert Cisneros3 Mar 20267 Apr 2026PurchaseStock$1,001 - $15,000+18.11%
Gilbert Cisneros18 Feb 20269 Mar 2026PurchaseStock$1,001 - $15,000+18.04%
Gilbert Cisneros12 Nov 202515 Dec 2025SaleStock$1,001 - $15,000N/A
Gilbert Cisneros16 Jun 202510 Jul 2025PurchaseStock$1,001 - $15,000N/A
Gilbert Cisneros23 Dec 202011 Jan 2021SaleStock$1,001 - $15,000N/A

See every trade

Sign in free to see the full trade history for this stock.

Select transactions to view their annotations on the chart

Stock Overview

Market Data

Market Cap

$3.39B

Volume

992.18K

Beta

1.93

P/E Ratio

21.27

Fundamentals

EPS

$2.00

Div. Yield

-

Open

$44.81

Day Range

$42.44 – $44.81

Company Information

Sector
Healthcare
Industry
Medical - Diagnostics & Research
Exchange
NASDAQ · USD
Country
US
CEO
Marc Stapley
IPO Date
2013-10-29
Website
www.veracyte.com

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Dec...

Earnings

Next Report

Q3 2026

3 Nov

EPS Est.

$0.43

Rev. Est.

$147.1M

Days Until

57

Recent Quarters

Q2 202630 Jul
EPS$0.54
Beat 31.6%
Q1 20265 May
EPS$0.52
Beat 52.9%
Q4 202525 Feb
EPS$0.53
Beat 29.8%
Q3 20254 Nov
EPS$0.51
Beat 59.4%
Q2 20256 Aug
EPS$0.44
Beat 41.9%
Q1 20257 May
EPS$0.31
Beat 55.0%
Q4 202424 Feb
EPS$0.07
Miss 30.0%
Q3 20246 Nov
EPS$0.19
Beat 603.7%
Q2 20246 Aug
EPS$0.07
Beat 333.3%
Q1 20247 May
EPS$-0.02
Beat 89.5%
Q4 202322 Feb
EPS$-0.39
Miss 457.1%
Q3 20237 Nov
EPS$-0.41
Miss 156.3%
Q2 20238 Aug
EPS$-0.12
Beat 25.0%
Q1 20234 May
EPS$-0.11
Beat 21.4%
Q4 202222 Feb
EPS$-0.05
Beat 66.7%
Q3 20222 Nov
EPS$-0.12
Beat 50.0%
Q2 20222 Aug
EPS$-0.13
Beat 38.1%
Q1 20223 May
EPS$-0.20
Beat 13.0%
Q4 202128 Feb
EPS$-0.15
Miss 7.1%
Q3 20219 Nov
EPS$-0.13
Beat 7.1%
Q2 202129 Jul
EPS$-0.13
Beat 48.0%
Q1 202110 May
EPS$-0.11
Beat 8.3%
Q4 202017 Feb
EPS$-0.14
Miss 55.6%
Q3 20202 Nov
EPS$-0.08
Beat 55.6%
Q2 202030 Jul
EPS$-0.22
Beat 0.0%
Q1 20206 May
EPS$-0.24
Miss 33.3%
Q4 201925 Feb
EPS$-0.15
Miss 66.7%
Q3 201922 Oct
EPS$-0.02
Beat 71.4%
Q2 201930 Jul
EPS$-0.05
Beat 44.4%
Q1 201930 Apr
EPS$-0.05
Beat 28.6%
Q4 201825 Feb
EPS$-0.08
Beat 38.5%
Q3 201829 Oct
EPS$-0.12
Beat 50.0%
Q2 201823 Jul
EPS$-0.18
Beat 33.3%
Q1 20181 May
EPS$-0.27
Miss 8.0%
Q4 201727 Feb
EPS$-0.24
Miss 14.3%
Q3 20176 Nov
EPS$-0.21
Beat 0.0%
Q2 201731 Jul
EPS$-0.22
Beat 12.0%
Q1 20173 May
EPS$-0.24
Beat 0.0%
Q4 20161 Mar
EPS$-0.14
Beat 46.1%
Q3 20163 Nov
EPS$-0.20
Beat 41.2%
Q2 20163 Aug
EPS$-0.40
Miss 25.0%
Q1 20165 May
EPS$-0.36
Miss 2.9%
Q4 201510 Mar
EPS$-0.29
Beat 6.5%
Q3 20155 Nov
EPS$-0.32
Beat 0.0%
Q2 201513 Aug
EPS$-0.35
Miss 12.9%
Q1 201514 May
EPS$-0.34
Beat 2.9%
Q4 201419 Mar
EPS$-0.36
Miss 2.9%
Q3 201413 Nov
EPS$-0.37
Miss 8.8%
Q2 201413 Aug
EPS$-0.31
Beat 8.8%
Q1 20148 May
EPS$-0.32
Miss 3.2%
Q4 201318 Mar
EPS$-0.42
Miss 13.5%
Q3 201325 Nov
EPS$-0.30
Q4 201231 Mar
EPS$-0.49
Q3 201231 Dec
EPS$-0.34
Q2 201230 Sept
EPS$-0.35

1 politician traded within 30 days

No dividend data available for this stock.

No stock split data available for this stock.

Similar Stocks

Based on congressional trading patterns

Smart Recommendations

LLY

Eli Lilly and Company

74
$1149.36-10.24 (-0.88%)
Healthcare
2 politicians both hold this
Same sector: Healthcare
2 politicians
View Stock

JNJ

Johnson & Johnson

74
$275.23-3.20 (-1.15%)
Healthcare
2 politicians both hold this
Same sector: Healthcare
2 politicians
View Stock

MSFT

Microsoft Corporation

69
$499.70-10.42 (-2.04%)
Technology
2 politicians both hold this
$34M in total holdings
2 politicians
View Stock

Frequently Asked Questions about VCYT

Which members of Congress have traded VCYT?
2 members of Congress have disclosed 12 trades in Veracyte, Inc. (VCYT) under the STOCK Act. The most active traders are Gilbert Cisneros and Josh Gottheimer.
When was VCYT most recently disclosed by Congress?
The most recent VCYT disclosure was a purchase by Gilbert Cisneros on 3 March 2026.
What is the total disclosed congressional trading volume for VCYT?
Members of Congress have disclosed approximately $64K in VCYT purchases and $32K in sales. These figures are midpoint estimates derived from the bracketed amount ranges used in STOCK Act filings.
How can I track new congressional trades in VCYT?
This VCYT page updates as soon as new STOCK Act disclosures are filed for Veracyte, Inc.. Every trade, politician, transaction date and amount range is surfaced above, typically within hours of the official filing appearing on the House or Senate disclosure portals.
Pelosi Tracker
PoliticiansBillsArticlesPortfoliosPricingAboutLegalTerms of ServicePrivacy Policy
Français
© 2026 - All rights reserved. Powered by Vantara Labs
Pelosi Tracker is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office or her representatives, or with any other member of Congress. Any use of her name is solely for the purpose of discussing publicly available information.The information provided by Pelosi Tracker is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.